| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| General and administrative costs | 281,161 | 292,360.5 | 213,658 | 221,127 |
| Loss from operations | -281,161 | -292,360.5* | -213,658 | -221,127 |
| Dividends earned on marketable securities held in trust account | 1,613,958 | 1,729,591.5 | 1,873,780 | 1,844,469 |
| Total other income | 1,613,958 | 1,729,591.5* | 1,873,780 | 1,844,469 |
| Net income | 1,332,797 | 1,437,231 | 1,660,122 | 1,623,342 |
| Basic EPS | 0.06 | 0.083 | 0.08 | NaN |
| Diluted EPS | 0.06 | 0.083 | 0.08 | NaN |
| Basic Average Shares | 17,250,000 | 17,250,000 | 17,250,000 | NaN |
| Diluted Average Shares | 17,250,000 | 17,250,000 | 17,250,000 | NaN |
Translational Development Acquisition Corp. (TDACW)
Translational Development Acquisition Corp. (TDACW)